Antifungal agents--clinical pharmacokinetics and drug interactions.
Achievement of therapeutic drug levels appears to be mandatory when antifungal agents are used for the treatment of manifest mycoses. Based on the marked interindividual variability of trough levels, Therapeutic Drug Monitoring is of increasing concern during treatment with itraconazole, voriconazole or posaconazole. In addition, a broad spectrum of potential drug interactions has to be kept in mind during triazole treatment. In contrast, echinocandins reveal a more comfortable class of antifungal agents in this regard with no obvious incidence of nephrotoxic side effects compared to amphotericin B and its lipid formulations.
Lipp
Hans-Peter
HP
University Clinic of Tuebingen, Roentgenweg, Tübingen, Germany. apotheke@med.uni-tuebingen.de
D000666:Amphotericin B / Q000493:pharmacokinetics; D000935:Antifungal Agents / Q000493:pharmacokinetics*; D004347:Drug Interactions; D054714:Echinocandins / Q000493:pharmacokinetics; D006801:Humans; D017964:Itraconazole / Q000493:pharmacokinetics; D009181:Mycoses / Q000188:drug therapy / Q000378:metabolism*; D011743:Pyrimidines / Q000493:pharmacokinetics; D014230:Triazoles / Q000493:pharmacokinetics; D065819:Voriconazole
D000935:Antifungal Agents; D054714:Echinocandins; D011743:Pyrimidines; D014230:Triazoles; D017964:Itraconazole; C101425:posaconazole; D000666:Amphotericin B; D065819:Voriconazole